Targeted therapy for small cell lung cancer

被引：2

作者：

Ganti, Apar Kishor ^{[1
,2
]}

Panwalkar, Amit W. ^{[1
]}

机构：

[1] Univ Nebraska, Med Ctr, Dept Internal Med, Div Hematol Oncol, Omaha, NE 68198 USA

[2] Omaha VA Med Ctr, Dept Internal Med, Omaha, NE USA

来源：

TARGETED ONCOLOGY | 2007年 / 2卷 / 02期

关键词：

Small cell lung cancer; Targeted therapy; Angiogenesis; Apoptosis; Vaccines;

D O I：

10.1007/s11523-007-0045-6

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Small cell lung cancer (SCLC) is very aggressive clinically, and current cytotoxic therapy has only a limited impact on survival. The development of targeted therapy for SCLC has lagged behind that of non-small cell lung cancer. Current drugs under investigation include those targeting the angiogenetic, apoptotic, sonic hedgehog, and mammalian target of rapamycin (mTOR) pathways. Vaccines seem to be promising adjunctive therapies. This review will present the available data on these agents. Common genetic abnormalities seen in SCLC, which could serve as potential future targets are also discussed.

引用

页码：89 / 97

页数：9

共 87 条

[1] Current guidelines for the management of small cell lung cancer [J].

Adjei, AA ;

Marks, RS ;

Bonner, JA .

MAYO CLINIC PROCEEDINGS, 1999, 74 (08) :809-816

[2] Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer [J].

Antonia, SJ ;

Mirza, N ;

Fricke, I ;

Chiappori, A ;

Thompson, P ;

Williams, N ;

Bepler, G ;

Simon, G ;

Janssen, W ;

Lee, JH ;

Menander, K ;

Chada, S ;

Gabrilovich, DI .

CLINICAL CANCER RESEARCH, 2006, 12 (03) :878-887

[3] Efficacy of the tyrosine kinase inhibitor gefitinib in a patient with metastatic small cell lung cancer [J].

Araki, J ;

Okamoto, I ;

Suto, R ;

Ichikawa, Y ;

Sasaki, J .

LUNG CANCER, 2005, 48 (01) :141-144

[4] Angiogenesis inhibitors in the treatment of small cell and non-small cell lung cancer [J].

Blackhall, FH ;

Shepherd, FA .

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2004, 18 (05) :1121-+

[5]

BODNER SM, 1992, ONCOGENE, V7, P743

[6]

BRENNAN J, 1991, CANCER RES, V51, P1708

[7] Matrix metalloproteinase inhibition: A review of anti-tumour activity [J].

Brown, PD ;

Giavazzi, R .

ANNALS OF ONCOLOGY, 1995, 6 (10) :967-974

[8] Epigenetic inactivation of RASSF14 in lung and breast cancers and malignant phenotype suppression [J].

Burbee, DG ;

Forgacs, E ;

Zöchbauer-Müller, S ;

Shivakumar, L ;

Fong, K ;

Gao, BN ;

Randle, D ;

Kondo, M ;

Virmani, A ;

Bader, S ;

Sekido, Y ;

Latif, F ;

Milchgrub, S ;

Toyooka, S ;

Gazdar, AF ;

Lerman, MI ;

Zabarovsky, E ;

White, M ;

Minna, JD .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (09) :691-699

[9] Lack of c-kit exon 11 activating mutations in c-KIT/CD117-positive SCLC tumour specimens [J].

Burger, H ;

den Bakker, MA ;

Stoter, G ;

Verweij, J ;

Nooter, K .

EUROPEAN JOURNAL OF CANCER, 2003, 39 (06) :793-799

[10] Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer [J].

Chan, S .

BRITISH JOURNAL OF CANCER, 2004, 91 (08) :1420-1424

← 1 2 3 4 5 6 7 8 9 →